Compare Bristol-Myers Squibb Co (BMY) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Snap Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $121.18B), while Snap Inc trades at $4.67 (market cap $7.84B). The key difference: Bristol-Myers Squibb Co is far larger — about 15.5× Snap Inc's market cap, and Bristol-Myers Squibb Co pays a 4.25% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| BMY | SNAP | |
|---|---|---|
Market Cap | $121.18B | $7.84B |
Sector | Health | Media |
52-Week High | $62.37 | $10.35 |
52-Week Low | $42.60 | $3.93 |
Enterprise Value | $157.12B | $9.22B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Snap Inc. (SNAP) trades at $4.665, down 0.32% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $5.93B in 2025, with a net loss of $460.49M, though losses have narrowed year-over-year. Recent news highlights the launch of high-priced AR glasses, which has drawn investor skepticism and contributed to stock volatility.
The outlook remains cautious; while cost-cutting and revenue growth offer potential, persistent losses, high debt, and competitive pressures pose significant risks. Analyst consensus is mixed with a $6.82 price target, suggesting moderate upside if execution improves, but the stock faces headwinds from weak profitability and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
